Investors

Press Releases

Press Releases

Date Title View
Toggle Summary Liquidia to Present at Cantor 2019 Global Healthcare Conference
RESEARCH TRIANGLE PARK, N.C. , Sept. 25, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, announced that Neal Fowler , Chief Executive Officer of Liquidia , will present a company overview at the
View HTML
Toggle Summary Liquidia Technologies Appoints Industry Veteran Dr. Joanna Horobin to Board of Directors
RESEARCH TRIANGLE PARK, N.C. , Sept. 12, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies , Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, today announced the appointment of Joanna Horobin , M.B., Ch.B., to the Company’s Board of Directors (the
View HTML
Toggle Summary Liquidia to Present at H.C. Wainwright Healthcare Conference
RESEARCH TRIANGLE PARK, N.C. , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, announced that Neal Fowler , Chief Executive Officer of Liquidia , will present a company overview at the H.C.
View HTML
Toggle Summary Liquidia to Present at Wedbush PacGrow Healthcare Conference
RESEARCH TRIANGLE PARK, N.C. , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, announced that Neal Fowler , Chief Executive Officer of Liquidia , will present a company overview at the 2019
View HTML
Toggle Summary Liquidia Technologies Reports Second Quarter 2019 Financial Results and Provides Corporate Update
On Track for Planned New Drug Application (NDA) Submission for LIQ861 in Late 2019 Continued Pipeline Progress Leveraging Proprietary PRINT® Technology Management to Host Webcast and Conference Call Today at 8:00 a.m. ET RESEARCH TRIANGLE PARK, N.C. , Aug.
View HTML
Toggle Summary Liquidia to Report Second Quarter 2019 Financial Results and Provide Corporate Update on August 8, 2019
RESEARCH TRIANGLE PARK, N.C. , Aug. 02, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT ® technology , today announced
View HTML
Toggle Summary Liquidia and GSK Restructure Collaboration Agreement
RESEARCH TRIANGLE PARK, N.C. , June 26, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology,
View HTML
Toggle Summary Liquidia Announces Clinical Update on INSPIRE; Targeting NDA Filing for LIQ861 in Late 2019
RESEARCH TRIANGLE PARK, N.C. , June 05, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company, today provided an update on the Phase 3 INSPIRE trial and development of LIQ861 for the treatment of pulmonary arterial
View HTML
Toggle Summary Liquidia to Present at Jefferies Healthcare Conference
RESEARCH TRIANGLE PARK, N.C. , June 03, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”) , a late-stage clinical biopharmaceutical company, announced that Neal Fowler , Chief Executive Officer of Liquidia , will present a company overview at the Jefferies 2019
View HTML
Toggle Summary Liquidia Appoints Seasoned Biopharmaceutical Industry Executive Dr. Richard Katz as Chief Financial Officer
RESEARCH TRIANGLE PARK, N.C. , May 22, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company, today announced the appointment of Richard D. Katz , M.D., as Chief Financial Officer (CFO). Dr.
View HTML